Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/88828
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSfanos, K.S.-
dc.contributor.authorAloia, A.L.-
dc.contributor.authorDe Marzo, A.M.-
dc.contributor.authorRein, A.-
dc.date.issued2012-
dc.identifier.citationNature Reviews Urology, 2012; 9(2):111-118-
dc.identifier.issn1759-4812-
dc.identifier.issn1759-4820-
dc.identifier.urihttp://hdl.handle.net/2440/88828-
dc.description.abstractXMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.-
dc.description.statementofresponsibilityKaren S. Sfanos, Amanda L. Aloia, Angelo M. De Marzo & Alan Rein-
dc.language.isoen-
dc.publisherNature Publishing Group-
dc.rights© 2012 Macmillan Publishers Limited. All rights reserved.-
dc.source.urihttp://dx.doi.org/10.1038/nrurol.2011.225-
dc.subjectAnimals-
dc.subjectHumans-
dc.subjectProstatic Neoplasms-
dc.subjectDNA, Viral-
dc.subjectMale-
dc.subjectXenotropic murine leukemia virus-related virus-
dc.titleXMRV and prostate cancer - a 'final' perspective-
dc.typeJournal article-
dc.identifier.doi10.1038/nrurol.2011.225-
pubs.publication-statusPublished-
Appears in Collections:Aurora harvest 7
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.